Long Term Study With B2036-PEG

Pfizer

Status and phase: Completed; Phase 3

Conditions: Acromegaly

Treatments: Drug: Pegvisomant

Study type: Interventional

Funder types: Industry

Identifiers

NCT00143416

A6291011

Details and patient eligibility

About

Primary objective: To investigate the efficacy and safety of Pegvisomant in Japanese patients with acromegaly.

Sex: All

Ages: 20 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with acromegaly who have received at least one dose of B2036-PEG in the preceding study (A6291009).

Exclusion criteria

• Switching to other therapeutic methods for acromegaly

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)